aTyr Pharma, Inc.
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at aTyr Pharma, Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 0.3765 $ to 1.10 $ · Last price: 0.363 $ (As of: September 18, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| aTyr Pharma, Inc. ATYR | 0.0 | – | -0.8 | -24,682.1 | – | -19.2 | -63.3 |
| Vertex Pharmaceuticals Inc VRTX | 128.6 | 30.9 | 24.5 | 55.0 | 38.1 | 9.6 | 31.3 |
| Regeneron Pharmaceuticals Inc REGN | 81.5 | 19.7 | 13.1 | 44.5 | 20.7 | 1.0 | 31.8 |
| argenx NV ARGX | 61.6 | 37.8 | 31.5 | 59.1 | 32.0 | 89.6 | 35.3 |
| Moderna Inc MRNA | 61.1 | – | 4.6 | -66.0 | -131.1 | -39.2 | 532.3 |
| Revolution Medicines Inc RVMD | 39.7 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 322.3 |
| BeiGene, Ltd. ONC | 39.7 | 62.6 | 34.1 | 88.9 | 19.1 | 40.2 | 2.3 |
| Royalty Pharma Plc RPRX | 32.2 | 31.5 | 19.6 | 95.8 | 100.3 | 5.1 | 68.6 |
| Alnylam Pharmaceuticals Inc ALNY | 31.8 | 60.3 | 28.4 | 79.7 | 23.0 | 65.2 | -47.0 |
| Median of companies shown | 39.7 | 34.7 | 19.6 | 55.0 | 21.8 | 5.1 | 31.8 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | – | -59 | -58 | -34.20 | -53 | 63 | 81 |
| 2017 | – | -47 | -48 | -26.16 | -42 | 64 | 89 |
| 2018 | – | -33 | -35 | -16.13 | -31 | 34 | 53 |
| 2019 | 0 | -23 | -24 | -7.03 | -20 | 21 | 36 |
| 2020 | 10 | -16 | -16 | -1.77 | -15 | 32 | 39 |
| 2021 | 0 | -34 | -34 | -1.77 | -33 | 109 | 116 |
| 2022 | 10 | -46 | -45 | -1.60 | -42 | 71 | 96 |
| 2023 | 0 | -55 | -50 | -0.94 | -33 | 91 | 121 |
| 2024 | 0 | -68 | -64 | -0.86 | -69 | 70 | 97 |
| 2025 | 0 | -78 | -74 | -0.80 | -62 | 67 | 94 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.18 | – | 0 | – | – | -13 | -13 |
| 2025: Q1 | -0.17 | – | 0 | -100.00 | – | -15 | -15 |
| 2025: Q2 | -0.22 | – | 0 | – | – | -14 | -14 |
| 2025: Q3 | -0.26 | – | 0 | – | -13,549.50 | -21 | -21 |
| 2025: Q4 | -0.14 | – | 0 | – | – | -12 | -12 |
| 2026: Q1 | -0.11 | – | 0 | – | – | -13 | -13 |
| 2026: Q2 | -0.11 | 50.00 | – | – | – | -9 | -10 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 9 of our scanner strategies — each hit links to the scanner.
Momentum & Trend
Risk & Weakness
- Bankruptcy Study: Stacked Warning Signals
- Below the 50- & 200-SMA
- Downward Momentum
- RS Weakness (≤10)
- Stage 4 (Downtrend)
- Stan Weinstein: Stage 4
- Stan Weinstein: Stage 4B-
- Weakness Cluster
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.42 | -0.50 – -0.36 | 0 | 48.3% | 7 |
| 12/31/2027 | -0.47 | -0.93 – -0.16 | 0 | -13.4% | 8 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -73.6%
- More than 10% revenue growth is expected for the coming year 0.0%
- Share count grows by less than 3% a year 48.4%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -32,683.9%
- Gross margin at 40% or higher and without meaningful erosion -717.4%
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA 67 m net cash
- Operating cash flow covers the profits of the last three years 24 m
- Return on capital at 15% or higher, or up versus two years ago -98.2%
- Insiders hold at least 10% or are net buyers 2.5%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -12.4%
- Exp. sales growth 3Y > 5% -100.0%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% -100.0%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -109.8%
- ROCE > 15% -98.2%
- Expected return > 10% -100.0%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
The company
About the Company
aTyr Pharma, Inc., ein Biotechnologieunternehmen in der klinischen Phase, befasst sich mit der Entdeckung und Entwicklung von Produktkandidaten, die die Biologie der tRNA-Synthetasen in neue Therapien gegen Fibrose und Entzündungen übersetzen, in den USA.
- Employees
- 58
- Headquarters
- San Diego, CA
- Address
- 10240 Sorrento Valley Road, 92121 San Diego, United States
- Phone
- 858 731 8389
- Website
- atyrpharma.com
- IPO Date
- 05/07/2015
- ISIN
- US0021202025
- Stock Split
- 1:14 on 07/01/2019
Management
| Name | Title | Birth Year |
|---|---|---|
| Sanjay S. Shukla M.D., M.S. | President, CEO & Director | 1972 |
| Jill M. Broadfoot CPA | Chief Financial Officer | 1962 |
| Nancy E. Denyes Krueger J.D. | General Counsel & Corporate Secretary | 1968 |
| Ashlee Dunston | Director of Investor Relations & Corporate Communications | – |
| Danielle Campbell | VP of Human Resource | – |
| Leslie Nangle Ph.D. | Vice President of Research | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.